Free Trial
NASDAQ:ESLA

Estrella Immunopharma (ESLA) Stock Price, News & Analysis

$0.80
-0.01 (-1.23%)
(As of 10/31/2024 ET)

About Estrella Immunopharma Stock (NASDAQ:ESLA)

Key Stats

Today's Range
$0.63
$0.88
50-Day Range
$0.81
$1.33
52-Week Range
$0.63
$3.23
Volume
71,757 shs
Average Volume
81,143 shs
Market Capitalization
$29.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Estrella Immunopharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
27th Percentile Overall Score

ESLA MarketRank™: 

Estrella Immunopharma scored higher than 27% of companies evaluated by MarketBeat, and ranked 883rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Estrella Immunopharma is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Estrella Immunopharma is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Estrella Immunopharma has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Estrella Immunopharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.17% of the float of Estrella Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Estrella Immunopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Estrella Immunopharma has recently decreased by 95.64%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Estrella Immunopharma does not currently pay a dividend.

  • Dividend Growth

    Estrella Immunopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.17% of the float of Estrella Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Estrella Immunopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Estrella Immunopharma has recently decreased by 95.64%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Estrella Immunopharma has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Estrella Immunopharma this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for ESLA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    55.10% of the stock of Estrella Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.35% of the stock of Estrella Immunopharma is held by institutions.

  • Read more about Estrella Immunopharma's insider trading history.
Receive ESLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

ESLA Stock News Headlines

The secret supplier behind NVIDIA, Tesla and Microsoft
The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.
Estrella Immunopharma, Inc. (ESLAW)
Entheon Biomedical Corp. (ENTBD)
See More Headlines

ESLA Stock Analysis - Frequently Asked Questions

Estrella Immunopharma's stock was trading at $1.11 at the start of the year. Since then, ESLA stock has decreased by 27.9% and is now trading at $0.7999.
View the best growth stocks for 2024 here
.

Estrella Immunopharma, Inc. (NASDAQ:ESLA) issued its quarterly earnings data on Friday, September, 27th. The company reported ($0.13) EPS for the quarter.

Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Estrella Immunopharma investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE).

Company Calendar

Last Earnings
9/27/2024
Today
10/31/2024
Next Earnings (Estimated)
11/18/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ESLA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-7,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.12 per share

Miscellaneous

Free Float
16,250,000
Market Cap
$29.10 million
Optionable
Not Optionable
Beta
0.18
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:ESLA) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners